Literature DB >> 1354594

Detection of retinoblastoma gene copy number in metaphase chromosomes and interphase nuclei by fluorescence in situ hybridization.

A Kallioniemi1, O P Kallioniemi, F M Waldman, L C Chen, L C Yu, Y K Fung, H S Smith, D Pinkel, J W Gray.   

Abstract

Fluorescence in situ hybridization (FISH) was applied to detect the copy number of the retinoblastoma (RB1) tumor suppressor gene in metaphase chromosomes and interphase nuclei. We used 14 lambda phage clones spanning the whole RB1 gene region as a probe and obtained a specific hybridization signal in normal metaphase chromosomes at 13q14. Normal interphase nuclei showed two RB1 signals in about 90% of cases, whereas two cell lines with cytogenetically defined deletions involving the RB1 gene showed only one hybridization signal in about 80% of the nuclei. Analogous changes were detected in metaphase chromosomes. Multicolor FISH with subsets of the phage clones allowed visualization of subregions within the 200-kb gene in interphase nuclei. Analysis of clinical breast cancer samples showed that most of the cells contained two copies of the RB1 gene, even when restriction fragment length polymorphism analysis showed loss of heterozygosity (LOH) at the RB1 locus. This indicates that LOH at the RB1 locus in breast cancer cells probably involves mechanisms other than physical deletion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354594     DOI: 10.1159/000133333

Source DB:  PubMed          Journal:  Cytogenet Cell Genet        ISSN: 0301-0171


  8 in total

1.  High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping.

Authors:  Daniel A Peiffer; Jennie M Le; Frank J Steemers; Weihua Chang; Tony Jenniges; Francisco Garcia; Kirt Haden; Jiangzhen Li; Chad A Shaw; John Belmont; Sau Wai Cheung; Richard M Shen; David L Barker; Kevin L Gunderson
Journal:  Genome Res       Date:  2006-08-09       Impact factor: 9.043

2.  Novel patterns of genome rearrangement and their association with survival in breast cancer.

Authors:  James Hicks; Alexander Krasnitz; B Lakshmi; Nicholas E Navin; Michael Riggs; Evan Leibu; Diane Esposito; Joan Alexander; Jen Troge; Vladimir Grubor; Seungtai Yoon; Michael Wigler; Kenny Ye; Anne-Lise Børresen-Dale; Bjørn Naume; Ellen Schlicting; Larry Norton; Torsten Hägerström; Lambert Skoog; Gert Auer; Susanne Månér; Pär Lundin; Anders Zetterberg
Journal:  Genome Res       Date:  2006-12       Impact factor: 9.043

3.  Isolation and characterisation of a panel of cosmids which allows unequivocal identification of chromosome deletions involving the RB1 gene using fluorescence in situ hybridisation.

Authors:  J K Cowell; R Jaju; H Kempski
Journal:  J Med Genet       Date:  1994-04       Impact factor: 6.318

Review 4.  Genetic analysis of breast cancer progression.

Authors:  S H Dairkee; H S Smith
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

5.  Solid-phase minisequencing confirmed by FISH analysis in determination of gene copy number.

Authors:  M Laan; K Grön-Virta; A Salo; P Aula; L Peltonen; A Palotie; A C Syvänen
Journal:  Hum Genet       Date:  1995-09       Impact factor: 4.132

6.  Expanding the Diversity of Imaging-Based RNAi Screen Applications Using Cell Spot Microarrays.

Authors:  Juha K Rantala; Sunjong Kwon; James Korkola; Joe W Gray
Journal:  Microarrays (Basel)       Date:  2013-04-11

7.  The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

Authors:  Jason I Herschkowitz; Xiaping He; Cheng Fan; Charles M Perou
Journal:  Breast Cancer Res       Date:  2008-09-09       Impact factor: 6.466

8.  Using high-density DNA methylation arrays to profile copy number alterations.

Authors:  Andrew Feber; Paul Guilhamon; Matthias Lechner; Tim Fenton; Gareth A Wilson; Christina Thirlwell; Tiffany J Morris; Adrienne M Flanagan; Andrew E Teschendorff; John D Kelly; Stephan Beck
Journal:  Genome Biol       Date:  2014-02-03       Impact factor: 13.583

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.